TAMPA, Fla. (Ivanhoe Newswire) — Breast cancer is the second most common cancer in American women. More than 300,000 women will be diagnosed this year. Researchers are working on a vaccine that could lead to prevention.
“Your general practitioner who normally says everything is fine goes pale,” said Barbara Popoli, while speaking in front of lawmakers to push for more funding for cancer research.
This is what happened when Popoli found out she had inflammatory breast cancer.
“Sixty to 80 percent chance I was going to die from this,” Popoli told Ivanhoe.
After chemotherapy, radiation and surgery, with her husband by her side, she enrolled in a breast cancer vaccine clinical trial. The vaccine is supposed to stop the cancer from ever coming back again.
Brian Czerniecki, M.D., the chair of the department of Breast Oncology at Moffitt Cancer Center in Tampa, Florida detailed, “I think it’s a potential game changer because we’ve actually shown that people lose this specific immune response early in the process of breast cancer development.” (Read Full Interview)
Dr. Czerniecki has been working on this vaccine for more than a decade.
“It’s meant to restore an immune response,” explained Dr. Czerniecki.
To make the vaccine, white blood cells are removed from the patient. Then those T cells are activated to become immune responders that target cancer cells. The customized vaccine is injected back into the patient.
Dr. Czerniecki said, “It showed a nice impact in that some people had their disease completely disappear before we operated on them.”
The vaccine can be given six to nine times to mostly patients who have HER2 positive disease. Eighty percent of those in the trial had an immune response.
Popoli said, “It’s revving up my T cells so my own body can fight this from here on out and hopefully never ever have to go through this again.”
The vaccine side effects could be fatigue, injection site reaction, and chills. The vaccine is still in clinical trials.
Contributors to this news report include: Cyndy McGrath, Supervising Producer; Emily Maza Gleason, Field Producer; Milvionne Chery, Assistant Producer; Roque Correa, Editor; Travis Bell, Videographer.
MEDICAL BREAKTHROUGHS – RESEARCH SUMMARY
TOPIC: Breast Cancer Vaccine Personalized
REPORT: MB #4233
BACKGROUND: An estimated one in every eight women will be diagnosed with breast cancer in her lifetime. Cancer occurs when cells grow out of control. In breast cancer, the cells form a malignant tumor that can spread, or metastasize, to distant parts of the body. Recent research on breast cancer shows that genetics play a role. Inheriting certain genes could mean you have a higher risk of developing the disease. This genetic link has caused some women who know they inherited a certain gene to get mastectomies as preventative measures. A mass or lump in the breast is the most common sign of breast cancer. Swelling or pain in the breast can also be signs of breast cancer.
DIAGNOSIS AND TREATMENT: Many gynecologists recommend regular screenings for breast cancer because some early stages of breast cancer do not display signs or symptoms. Mammograms, or X-rays of the breast, involve compressing the breast between two plates to scan tissue. If the mammogram yields an abnormal result, the doctor will recommend a diagnostic mammogram, which consists of more images, of the suspicious area. Then if there is still cause for concern, a biopsy may be taken. The biopsy can be taken by inserting a needle to obtain a small sample of the area or removing a mass through surgery. Researchers have found that cancer treatments have become less effective when targeting or even recognizing the HER2 protein in advance stages of breast cancer, leading to a poor prognosis for some women.
NEW TECHNOLOGY: Researchers at Moffitt Cancer center have developed a vaccine that can help the immune system recognize the HER2 protein in breast cancer cells. The vaccine from immune cells, called dendritic cells, are harvested from each patient and then used to create a personalized vaccine. The researchers conducted a clinical trial on 54 women with HER2 early stage breast cancer. The patients in the trial were injected their own personalized vaccine once a week for six weeks. About 80 percent of the patients had a detectable immune response.
FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT:
If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at firstname.lastname@example.org